Finlandia - finlandese - Fimea (Suomen lääkevirasto)

octapharma ab - albumin, human - infuusioneste, liuos - 50 g/l - albumiini

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

octapharma ab - albumin, human - infuusioneste, liuos - 200 g/l - albumiini

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

octapharma ab - albumin, human - infuusioneste, liuos - 40 g/l - albumiini

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

octapharma ab - albumin, human - infuusioneste, liuos - 250 g/l - albumiini

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

octapharma ab - antithrombine iii humane - infuusiokuiva-aine ja liuotin, liuosta varten - antitrombiini

Unione Europea - finlandese - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiset aineet - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

Unione Europea - finlandese - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastiset aineet - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

octapharma ab - human normal immunoglobulin - injektioneste, liuos - 165 mg/ml - ihmisen normaali immunoglobuliini ekstravaskulaariseen käyttöön

Unione Europea - finlandese - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - muut antineoplastiset aineet - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Unione Europea - finlandese - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastiset aineet - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).